Therapeutics News and Research

RSS

Selcia completes drug discovery project with ExonHit Therapeutics using fragment screening technology

Selcia Ltd today announced the successful completion of a drug discovery project with ExonHit Therapeutics SA, using Selcia's fragment screening technology. Novel and weak affinity hits were identified from Selcia's Fragment Library, using their proprietary CEfrag technique.

28 Feb 2011

FUJIFILM enters definitive agreement to acquire Merck

FUJIFILM Corporation and Merck, known as MSD outside the United States and Canada, today announced they have entered into a definitive agreement by which Fujifilm will acquire the Merck BioManufacturing Network, a leading provider of contract manufacturing and development services for the biopharmaceutical industry and wholly owned by Merck.

28 Feb 2011

Targets against MRSA in microgravity

NASA astronauts onboard Space Shuttle Discovery's final mission to the International Space Station (ISS) will carry out the eleventh scientific payload for Astrogenetix, a commercial biotech company based out of Austin, Texas. The research on STS-133 will focus on changes that occur to methicillin-resistant Staphylococcus aureus (MRSA) in microgravity, which can be targeted to create new vaccines and therapeutics.

25 Feb 2011

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today announced the publication of the first reported case in which adenovirus infection was successfully eradicated following treatment with its broad-spectrum antiviral drug, CMX001.

25 Feb 2011

Signal files complaint against Med Biogene and Precision Therapeutics in Supreme Court

Med Biogene Inc., a Vancouver-based life sciences company, has been charged with fraud, and Pittsburgh-based Precision Therapeutics, Inc., was charged with tortious interference in an amended complaint filed today by Signal Genetics in Supreme Court for the County of New York.

25 Feb 2011

Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells

Stemline Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells (CSCs), today announced that it holds the license, from the University of Pittsburgh ("Pitt"), for the exclusive worldwide rights to a clinically active oncology vaccine directed to multiple defined targets on tumor bulk and CSCs.

25 Feb 2011

Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF

Vertex Pharmaceuticals Incorporated today announced positive results from the Phase 3 STRIVE study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis.

24 Feb 2011

ImmunoCellular to receive gross proceeds of $8.1M from sale of 5.2M units

ImmunoCellular Therapeutics, Ltd., announced it has entered into securities purchase agreements with certain institutional and other investors in connection with a private placement financing.

24 Feb 2011

UBC study shows Canadians and Americans receive different drug information online

Americans and Canadians are getting vastly different search results when they look up prescription drug information online, says a study by researchers at the University of British Columbia.

24 Feb 2011

CST, Astellas Pharma enter commercialization partnership for cancer diagnostic, therapeutic products

Cell Signaling Technology, Inc. of Danvers, MA announced today a joint commercialization partnership with Astellas Pharma, Inc. of Tokyo, Japan focused on the delivery of personalized cancer therapeutics and diagnostics.

From Cell Signaling Technology 24 Feb 2011

Aestus commences ATx08-001 phase 2 trial to evaluate efficacy of novel pain therapeutic

Aestus Therapeutics, Inc., announced today that it has initiated screening of patients for a clinical trial to evaluate the efficacy of its novel pain therapeutic, ATx08-001. This placebo-controlled, two-dose level study will test the efficacy of ATx08-001 in reducing the pain following an outbreak of shingles.

23 Feb 2011

Multi-national consortium develops new approaches to cure the flu

Pharmacelsus GmbH announces its participation in the 4 year multi-national research cooperation project “FLUCURE” supported by the European Union with the goal of developing novel, small molecule based therapeutics for respiratory diseases caused by influenza viruses. The consortium also joined Vironova AB and Beactica AB (Sweden), Pike Pharma GmbH (Switzerland) and university-based research groups from Italy, Germany, Bulgaria, Lithuania, and the Netherlands.

23 Feb 2011

Pharmacelsus participates in FLUCURE project to develop novel therapeutics against influenza

Pharmacelsus GmbH announces its participation in the 4 year multi-national research cooperation project "FLUCURE" supported by the European Union with the goal of developing novel, small molecule based therapeutics for respiratory diseases caused by influenza viruses.

23 Feb 2011

Norgine, Tranzyme commence dosing in ulimorelin Phase 3 study for restoring GI function after surgery

Tranzyme Pharma and Norgine B.V., have initiated dosing of ulimorelin in the first of two, Phase 3 pivotal studies - ULISES. Ulimorelin is Tranzyme's intravenous promotility agent in development for the management of postoperative ileus in hospital and acute care settings.

23 Feb 2011

Omeros announces license agreement with Daiichi Sankyo for PDE7 inhibitors

Omeros Corporation today announced that its exclusive license to phosphodiesterase 7 inhibitors from Daiichi Sankyo Co., Ltd. has been amended to include addiction and compulsive disorders in the field of use.

23 Feb 2011

USPTO issues patent to Silence Therapeutics' siRNA technology

Silence Therapeutics plc announces the issuance of United States patent 7,893,245, titled "Interfering RNA Molecules," by the United States Patent and Trademark Office.

23 Feb 2011

American Journal of Clinical Oncology publishes CTI's OPAXIO phase II results against esophageal cancer

Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.

23 Feb 2011

Forest Labs enters definitive merger agreement to acquire Clinical Data

Forest Laboratories, Inc. and Clinical Data, Inc. today announced that they have entered into a definitive merger agreement pursuant to which Forest will acquire Clinical Data, a specialty pharmaceutical company focused on the development of first-in-class and best-in-category therapeutics, for $30.00 per share in cash plus contingent consideration of up to $6.00 per share that may be paid upon achievement of certain commercial milestones related to Viibryd.

22 Feb 2011

Pieris: New interim PRS-050 Phase I data against cancer to be presented at Tri-Conference in California

Pieris AG announced today the upcoming presentation of new preclinical and interim Phase I clinical trial data for its PRS-050 Anticalin(r) program, currently under evaluation for the treatment of cancer.

22 Feb 2011

Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions

Fate Therapeutics, Inc. presented encouraging preliminary data from an ongoing Phase 1b clinical trial of FT1050 at the 2011 BMT Tandem Meetings in Honolulu, Hawaii.

22 Feb 2011

Therapeutics News and Research

Selcia completes drug discovery project with ExonHit Therapeutics using fragment screening technology

FUJIFILM enters definitive agreement to acquire Merck

Targets against MRSA in microgravity

Journal of Clinical Virology publishes positive outcome from CMX001 treatment against AdV infection

Signal files complaint against Med Biogene and Precision Therapeutics in Supreme Court

Stemline licenses clinically active oncology vaccine for dual targeting of tumor bulk and cancer stem cells

Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF

ImmunoCellular to receive gross proceeds of $8.1M from sale of 5.2M units

UBC study shows Canadians and Americans receive different drug information online

CST, Astellas Pharma enter commercialization partnership for cancer diagnostic, therapeutic products

Aestus commences ATx08-001 phase 2 trial to evaluate efficacy of novel pain therapeutic

Multi-national consortium develops new approaches to cure the flu

Pharmacelsus participates in FLUCURE project to develop novel therapeutics against influenza

Norgine, Tranzyme commence dosing in ulimorelin Phase 3 study for restoring GI function after surgery

Omeros announces license agreement with Daiichi Sankyo for PDE7 inhibitors

USPTO issues patent to Silence Therapeutics' siRNA technology

American Journal of Clinical Oncology publishes CTI's OPAXIO phase II results against esophageal cancer

Forest Labs enters definitive merger agreement to acquire Clinical Data

Pieris: New interim PRS-050 Phase I data against cancer to be presented at Tri-Conference in California

Positive preliminary data from Fate Therapeutics FT1050 Phase 1b trial in patients with life-threatening conditions

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News